Due to the involvement of DYRK1A in the pathophysiological process of AD, this protein is recognized as a potential therapeutic target for this disease, which has led some research groups to synthesize and evaluate new compounds as potential inhibitors of this protein [10]. Here, DYRK1A is linked to Alzheimer disease.